Liu Yang

Liu Yang

Auto-generated profile, based on publicly available information

Liu Yang

The Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
FMFolasade P. May
Folasade P. May
LYLiu Yang
Liu Yang
ECEdgar Corona
Edgar Corona
BGBeth A. Glenn
Beth A. Glenn
RBRoshan Bastani
Roshan Bastani

18 March 2021 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
YFYvonne N. Flores
Yvonne N. Flores
GDGeetanjali D. Datta
Geetanjali D. Datta
LYLiu Yang
Liu Yang
ECEdgar Corona
Edgar Corona
DDDivya Devineni
Divya Devineni
FMFolasade P. May
Folasade P. May
Background: Liver cancer is one of the most rapidly increasing cancers in the United States, and hepatocellular carcinoma (HCC) is its most common form. Disease burden and risk factors differ by sex and race/ethnicity, but a comprehensive analysis of disparities by socioeconomic status (SES) is lacking. We examined the relative impact of race/ethnicity, sex, and SES on HCC incidence, stage, and survival. Methods: We used Surveillance, Epidemiology, and End Results (SEER) 18 data to identify histologically confirmed cases of HCC diagnosed between January 1, 2000 and December 31, 2015. We calculated age-adjusted HCC incidence, stage at diagnosis (local, regional, distant, unstaged), and 5-year survival, by race/ethnicity, SES and sex, using SEER*Stat version 8.3.5. Results: We identified 45,789 cases of HCC. Incidence was highest among low-SES Asian/Pacific Islanders (API; 12.1) and lowest in high-SES Whites (3.2). Incidence was significantly higher among those with low-SES compared with high-SES for each racial/ethnic group (P < 0.001), except American Indian/Alaska Natives (AI/AN). High-SES API had the highest percentage of HCC diagnosed at the local stage. Of all race/ethnicities, Blacks had the highest proportion of distant stage disease in the low- and high-SES groups. Survival was greater in all high-SES racial/ethnic groups compared with low-SES (P < 0.001), except among AI/ANs. Black, low-SES males had the lowest 5-year survival. Conclusions: With few exceptions, HCC incidence, distant stage at diagnosis, and poor survival were highest among the low-SES groups for all race/ethnicities in this national sample. Impact: HCC prevention and control efforts should target low SES populations, in addition to specific racial/ethnic groups.

5 September 2019 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
JMJohn N. Mafi
John N. Mafi
FMFolasade P. May
Folasade P. May
KKKatherine L. Kahn
Katherine L. Kahn
MCMichelle Chong
Michelle Chong
ECEdgar Corona
Edgar Corona
CSCatherine Sarkisian
Catherine Sarkisian

19 April 2020 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
VCVivy T. Cusumano
Vivy T. Cusumano
ECEdgar Corona
Edgar Corona
DPDiana Partida
Diana Partida
LYLiu Yang
Liu Yang
CYChristine Yu
Christine Yu
FMFolasade P. May
Folasade P. May
The fecal immunochemical test (FIT) is the second most commonly used colorectal cancer (CRC) screening modality in the United States; yet, follow-up of abnormal FIT results with diagnostic colonoscopy is underutilized. Our objective was to determine patient-reported barriers to diagnostic colonoscopy following abnormal FIT in an academic healthcare setting. We included patients age 50–75 with an abnormal FIT result between 1/1/2015 and 10/31/2017 and no documented follow-up diagnostic colonoscopy. We abstracted demographic data from the electronic health record (EHR). Study personnel conducted telephone surveys with patients to confirm colonoscopy completion and elicit data on notification of FIT results and barriers to colonoscopy. We also provided brief verbal education about diagnostic colonoscopy. We calculated frequencies of demographic data and survey responses and compared survey responses by interest in colonoscopy after education. We surveyed 67 patients. Fifty-one were aware of the abnormal FIT result, and a majority learned of the abnormal FIT result by direct communication with providers (19, 37.3%) or EHR messaging (11, 21.6%). Overall, fifty-three patients (79.1%) confirmed lack of colonoscopy, citing provider-related (19, 35.8%), patient-related (16, 30.2%), system-related (1, 1.9%), or multifactorial (17, 32.1%) reasons. Lack of knowledge of FIT result (14, 26.4%) was most common. After brief education, 20 (37.7%) patients requested colonoscopy. Patients with an abnormal FIT reported various multi-level barriers to diagnostic colonoscopy after abnormal FIT, including knowledge of FIT results. When provided with brief education, participants expressed interest in diagnostic colonoscopy. Future efforts will evaluate interventions to improve colonoscopy follow-up.

1 February 2020 in Gastroenterology
Verified
Journal Article
Closed access
FCFrank W. Chen
Frank W. Chen
WLWendi G. LeBrett
Wendi G. LeBrett
LYLiu Yang
Liu Yang
LCLin Chang
Lin Chang

22 April 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AMAnthony Myint
Anthony Myint
ECEdgar Corona
Edgar Corona
LYLiu Yang
Liu Yang
BNBao Sean Nguyen
Bao Sean Nguyen
CLChristina Lin
Christina Lin
FMFolasade P. May
Folasade P. May
Individuals diagnosed with colorectal adenomas with high-risk features during screening colonoscopy have increased risk for the development of subsequent adenomas and colorectal cancer. While US guidelines recommend surveillance colonoscopy at 3 years in this high-risk population, surveillance uptake is suboptimal. To inform future interventions to improve surveillance uptake, we sought to assess surveillance rates and identify facilitators of uptake in a large integrated health system. We utilized a cohort of patients with a diagnosis of ≥ 1 tubular adenoma (TA) with high-risk features (TA ≥ 1 cm, TA with villous features, TA with high-grade dysplasia, or ≥ 3 TA of any size) on colonoscopy between 2013 and 2016. Surveillance colonoscopy completion within 3.5 years of diagnosis of an adenoma with high-risk features was our primary outcome. We evaluated surveillance uptake over time and utilized logistic regression to detect factors associated with completion of surveillance colonoscopy. The final cohort was comprised of 405 patients. 172 (42.5%) patients successfully completed surveillance colonoscopy by 3.5 years. Use of a patient reminder (telephone, electronic message, or letter) for due surveillance (adjusted odds = 1.9; 95%CI = 1.2–2.8) and having ≥ 1 gastroenterology (GI) visit after diagnosis of an adenoma with high-risk features (adjusted odds = 2.6; 95%CI = 1.6–4.2) significantly predicted surveillance colonoscopy completion at 3.5 years. For patients diagnosed with adenomas with high-risk features, surveillance colonoscopy uptake is suboptimal and frequently occurs after the 3-year surveillance recommendation. Patient reminders and visitation with GI after index colonoscopy are associated with timely surveillance completion. Our findings highlight potential health system interventions to increase timely surveillance uptake for patients diagnosed with adenomas with high-risk features.